Evidence map›Paper›PMID 35901346›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Novel Approach Using shRNA of IQGAP1 for Colon Cancer Therapy: HCT116 as a Surrogate Model Colorectal Carcinoma

Khairy M M A Zoheir, Khaled Mahmoud, Gamal I Harisa, Abdelkader Ashour, Hala E Abdel-Hamied, Amro A Amara, Karima F Mahrous, Ahmed A Abd-Rabou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Khairy M M A ZoheirCell Biology Department, Biotechnology Research Institute, National Research Centre, 33 Bohouth St., 12622, Dokki, Cairo, Egypt.ORCID 0000-0003-0896-4499
Khaled MahmoudPharmacognosy Department, National Research Centre, El-Behooth St., 12622 Dokki, Cairo, Egypt.ORCID 0000-0002-1364-4951
Gamal I HarisaPharmaceutical Industries, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Abdelkader AshourDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University, 41636 Kantara Branch, Egypt.
Hala E Abdel-HamiedDepartment of Pharmacology and Toxicology, College of Pharmacy, Al-Azhar University, Cairo, Egypt.
Amro A AmaraProtein Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications, Alexandria, Egypt.
Karima F MahrousCell Biology Department, Biotechnology Research Institute, National Research Centre, 33 Bohouth St., 12622, Dokki, Cairo, Egypt.
Ahmed A Abd-RabouHormones Department, Medicine and Clinical Studies Research Institute, National Research Centre, Cairo, 12622 Egypt.
Al-Azhar University · EGCity of Scientific Research and Technological Applications · EGNational Research Centre · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal carcinoma (CRC) represents life-threatening problems worldwide. IQ motif containing GTPase activating protein 1 (IQGAP1) is acting as oncogenesis regulators. RNAi is proposed as promising cancer therapeutics.

objectiveThe objective of this work to explore the consequences of the IQGAP1 silence as a goal for treating CRC using the HCT166 cells as a model for human colon cancer.

methodsRNAi technology was used to design a short specific sequence of RNA (shRNA) to silence the IQGAP1 oncogene. The impact of IQGAP1 silencing on IQGAPs, Ras, IL-8, and TRAIL was investigated. Furthermore, the effect of IQGAP1 silencing on cell viability, proliferation, apoptosis, and invasive capacity was investigated.

resultsThe present results revealed that IQGAP1 shRNA-treated HCT166 cells showed no invasive capacity compared to the control cells. The silencing of IQGAP1 induced remarkable downregulation of IQGAP1, RAS (H&K), IL-8, CXCR1, CXCR2, NF-kB, BCL-2, and apoptosis of HCT166 cells. On the contrary, IQGAP2, IQGAP3, DR4, DR5, CASP-3, and BAX genes were significantly up-regulated.

conclusionThe IQGAP1 regulates the expression of IQGAPs, Ras, IL-8 receptors, and the apoptotic network. Therefore, the silence of IQGAP1 is a promising strategy for colon cancer therapy.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsGTPase-Activating ProteinsHumansInterleukin-8ras GTPase-Activating ProteinsRNA, Small InterferingGTPase-Activating ProteinsInterleukin-8IQGAP2 protein, humanIQGAP3 protein, humanIQ motif containing GTPase activating protein 1ras GTPase-Activating ProteinsRNA, Small InterferingApoptosisCell migrationColon cancerIQGAP1shRNA

Identifiers

PMID35901346
PMCPMC9727335
OpenAlexW4288388842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.